Barclays Cite Favorable Long-Term Outlook For Legend Biotech Corporation (LEGN) Despite Near-Term Expectation Revisions

Legend Biotech Corporation (NASDAQ:LEGN) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.

Barclays Cite Favorable Long-Term Outlook For Legend Biotech Corporation (LEGN) Despite Near-Term Expectation Revisions

Legend Biotech Corporation (NASDAQ:LEGN) tops our list of the best healthcare stocks.

TheFly reported on February 4 that Barclays lowered its price target on LEGN to $80 from $90 and maintained an Overweight rating on the shares. Although the long-term forecast for the company’s clinical projects is still favorable, the revision comes ahead of the firm’s Q4 earnings preview for the biotechnology industry, which reflects a larger reconsideration of near-term expectations.

Separately, Legend Biotech Corporation (NASDAQ:LEGN) announced its strategic targets for 2026 and gave an update on its clinical and commercial developments last month, on January 12. As of early 2026, CARVYKTI was still the market leader for multiple myeloma CAR-T cell treatment, treating over 10,000 patients. By using CARVYKTI globally and utilizing its CAR-T platform for frontline multiple myeloma and future in vivo and allogeneic initiatives, the business hopes to turn a profit by 2026. With cash, cash equivalents, and time deposits of almost $1.0 billion as of September 30, 2025, the firm has a financial runway beyond 2026 and can support its ambitions for transformative growth and operating profit for the entire organization.

Legend Biotech Corporation (NASDAQ:LEGN) is a U.S. biotech innovator pioneering next‑generation cell therapies, including FDA‑approved CAR‑T treatments for multiple myeloma. It advances cutting‑edge immune‑based platforms and proprietary technologies to redefine cancer care and expand transformative therapeutic options worldwide.

While we acknowledge the potential of LEGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LEGN and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.

Disclosure: None.